The risk of bladder cancer in korean diabetic subjects treated with pioglitazone. - Wikidata - awgldk - TriplyDB

The risk of bladder cancer in korean diabetic subjects treated with pioglitazone.

The risk of bladder cancer in korean diabetic subjects treated with pioglitazone.

http://www.wikidata.org/entity/Q36365241

about

The current role of thiazolidinediones in diabetes management.A retrospective study on finding correlation of pioglitazone and incidences of bladder cancer in the Indian population.Thiazolidinediones and associated risk of bladder cancer: a systematic review and meta-analysis Pioglitazone use and risk of bladder cancer: population based cohort study.Pioglitazone and the risk of bladder cancer: An Indian retrospective cohort study Rosiglitazone Use and the Risk of Bladder Cancer in Patients With Type 2 Diabetes.Effects of co-administration of candesartan with pioglitazone on inflammatory parameters in hypertensive patients with type 2 diabetes mellitus: a preliminary report.Risk of bladder cancer among patients with diabetes treated with a 15 mg pioglitazone dose in Korea: a multi-center retrospective cohort study.Metabolic Surgery for Type 2 Diabetes in Patients with a BMI of <35 kg/m(2): A Surgeon's Perspective.The future of thiazolidinedione therapy in the management of type 2 diabetes mellitus.Refocusing Peroxisome Proliferator Activated Receptor-α: A New Insight for Therapeutic Roles in Diabetes.A review on thiazolidinediones and bladder cancer in human studies.Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis.Thiazolidinedione drugs in the treatment of type 2 diabetes mellitus: past, present and future.Pioglitazone and the Risk of Bladder Cancer: A Meta-Analysis.Development of vascular complications and bladder carcinoma in diabetics using pioglitazone: A five-year Indian review Ten-year observational follow-up of PROactive: a randomized cardiovascular outcomes trial evaluating pioglitazone in type 2 diabetes.Pioglitazone does not increase the risk of type II diabetes in patients with bladder cancer: A retrospective study.Letter: the risk of bladder cancer in korean diabetic subjects treated with pioglitazone (diabetes metab j 2012;36:371-8).Global and Regional Effects of Bladder Cancer Risk Associated with Pioglitazone Therapy in Patients with Diabetes.Pioglitazone and bladder cancer risk: a systematic review and meta-analysis.Pioglitazone use in patients with diabetes and risk of bladder cancer: a systematic review and meta-analysis.

P2860

Q30250347-0C958AFC-324F-46E4-85B0-A3A94EF7D992 Q33750513-A443E369-FB66-45A2-97B7-51A8D3DEC3E6 Q34065266-9FBA91AA-BAFB-4721-942C-E64EAC1146B7 Q34676639-DDCC3E9D-DC37-4D39-8FA4-597AD8F6BE09 Q36050377-BEFBA736-91C2-44C2-AF72-14D6A26633E3 Q36581133-C94BA389-011D-43AC-A481-5F888C426A7B Q36874242-481EA7A0-AAA0-49C7-B70C-75878110D881 Q37583052-EE999EDD-ADDD-4E9C-A6BC-8F0E843219B1 Q38096980-2BFC033D-CD20-4B23-95C2-F6C4368454E0 Q38102596-3D42736A-416C-4E8E-BA0B-83289645E7A7 Q38160494-9EAC7A9B-CA82-410A-A346-EFC424ECD36B Q38193601-F9530C3C-D4EA-478D-B2B4-C31C8CA6E90D Q38417421-298EA0F5-BA1E-41D7-92D2-6663C66B834C Q38641190-975C2125-30DF-4D60-AAF3-6A58E5157625 Q38721611-3EA284D6-83F1-4AE9-81C5-70E9B1F98532 Q38933618-A84C6565-2FB7-4754-9FBA-D9EB181B3D22 Q41107308-00ABDED9-5317-43EC-A3FF-060D0A407A23 Q42137557-B18EE0FE-6938-4965-BBAE-7CEFD955E26B Q43242358-59D98D96-CF67-44D9-80F7-7B687299BE83 Q45073276-58D5D8A3-6B70-4066-A3D8-4A711F9B5B1D Q55079635-A8096B51-2749-44E7-90AF-A174A3794CB6 Q55406042-D3D88DBA-D330-4BFB-BF78-D5706D718176

P2860

The risk of bladder cancer in korean diabetic subjects treated with pioglitazone.

http://www.wikidata.org/entity/Q36365241

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

The risk of bladder cancer in korean diabetic subjects treated with pioglitazone.

@ast

The risk of bladder cancer in korean diabetic subjects treated with pioglitazone.

@en

type

label

The risk of bladder cancer in korean diabetic subjects treated with pioglitazone.

@ast

The risk of bladder cancer in korean diabetic subjects treated with pioglitazone.

@en

prefLabel

The risk of bladder cancer in korean diabetic subjects treated with pioglitazone.

@ast

The risk of bladder cancer in korean diabetic subjects treated with pioglitazone.

@en

P1433

Q36365241-BC543020-D40B-4210-A7BB-D6DD43CA8E7A

P1476

Q36365241-63A8223B-BF08-4011-97F9-EAEC46F526C6

P2093

Q36365241-1D563998-E85B-4C30-85EB-09B90FC5ABB0

Q36365241-748D041C-D019-44CE-9365-CADF4FFD6645

Q36365241-931550C2-F87A-4DB4-A709-0D21135AD4E9

P2860

Q36365241-1777489D-6339-464B-91BA-18B597A6F5A5

Q36365241-24523F6A-34F9-41EA-9C70-D79D78AE518F

Q36365241-3C06043A-634D-4912-8FC2-AC6172355A69

Q36365241-45C5A913-F24A-482F-8D45-C3825E2C483D

Q36365241-4F1E6806-5CF0-4430-A63C-85350BF0C645

Q36365241-5CBC4560-9BF0-416F-B721-B1E2BD3D7263

Q36365241-5E8E5257-F9EA-4DD2-9882-2B09B6B19AE4

Q36365241-6AE4F6E8-B744-425C-A7FD-B8BFED54A1B4

Q36365241-7DD502FC-CBFC-4232-A5DB-8DFF4A70D750

Q36365241-8426D123-9FB1-4ABA-9053-FBE708C59581

P304

Q36365241-6C97921D-2A51-4762-B956-0CB7BF498AEF

P31

Q36365241-21BA3335-C5CD-4BE6-8F3C-272E336D0499

P356

Q36365241-78E83839-B15C-4A91-BBBF-91621E3D6018

P433

Q36365241-7FA48356-FA4C-4368-9231-8C12522064A8

P478

Q36365241-82029D47-7411-4A8B-A95D-549C6C45985E

P50

Q36365241-5DF548C2-67BE-4A96-9D10-E833EB17C37B

Q36365241-9EA207CC-024E-455D-9439-474D996C0AD8

Q36365241-A6E40DE5-0D8F-4EE0-BB73-EE8CC86510C4

P577

Q36365241-D7217912-782E-4DA6-AD7C-A9301F4C4729

P5875

Q36365241-676F5C61-97D4-4416-85EE-EA3ED2D4A9B9

P698

Q36365241-B54F4C66-C4E9-44BE-8549-E9E37ACDA2E9

P932

Q36365241-5EE39A28-F286-49A9-9854-9F68AA48F6EF

P356

DMJ.2012.36.5.371

P1433

Diabetes & metabolism journal

P1476

The risk of bladder cancer in korean diabetic subjects treated with pioglitazone

@en

P2093

Byung-Wan Lee

http://www.w3.org/2001/XMLSchema#string

Hyun Chul Lee

http://www.w3.org/2001/XMLSchema#string

Kwang Joon Kim

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths

Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial

Safety and tolerability of pioglitazone in high-risk patients with type 2 diabetes: an overview of data from PROactive.

Risk of bladder cancer among diabetic patients treated with pioglitazone: interim report of a longitudinal cohort study.

Assessing the association of pioglitazone use and bladder cancer through drug adverse event reporting

Diabetes and risk of bladder cancer: evidence from a case-control study in New England

The prediabetic period: review of clinical aspects.

Diabetes and cancer: is diabetes causally related to cancer?

2011 clinical practice guidelines for type 2 diabetes in Korea

Pioglitazone and bladder cancer: a population-based study of Taiwanese.

P304

371-378

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.4093/DMJ.2012.36.5.371

http://www.w3.org/2001/XMLSchema#string

P433

5

http://www.w3.org/2001/XMLSchema#string

P478

36

http://www.w3.org/2001/XMLSchema#string

P50

P577

2012-10-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

232934584

http://www.w3.org/2001/XMLSchema#string

P698

23130322

http://www.w3.org/2001/XMLSchema#string

P932

3486984

http://www.w3.org/2001/XMLSchema#string